The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Mumbai: Cipla Limited has announced that the Company has completed an investment of approx. ZAR 900 million in Cipla Medpro South Africa Proprietary Limited, South Africa, a wholly owned subsidiary in ...

Cipla finished the day at Rs 1464.15, showing a fall of 1.22% in its market value. Cipla's shares are currently priced at Rs 1465.95, reflecting a 1.09% decrease today, alongside a return of 3.38% ...

So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the niche launches. And if you see, the commentary has also been very positive.

Revenue 25,774.09 22,753.12 21,763.34 19,159.59 ...

The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.

The force said: "The liquid is believed to be a type of homemade 'chilli spray' with no strong acid or alkaline ingredients." A youth has been arrested on suspicion of attempting to cause grievous ...